Walking Forward - American Indian Participation in Cancer Clinical Trials

向前迈进——美洲印第安人参与癌症临床试验

• 批准号: 8335654
• 负责人: DANIEL G PETEREIT
• 金额: $ 14万
• 依托单位: RAPID CITY REGIONAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8335654
• 关键词: Address; Adverse reactions; American Indians; Area; Brachytherapy; Client; Clinical; Clinical Trials; Common Neoplasm; Communities; Community Hospitals; Complex; DNA Microarray Chip; Diagnosis; Diagnostic Neoplasm Staging; Disease; Disorder by Site; Enrollment; Evaluation; Future; Gene Expression; Genes; Genetic; Genetic Risk; Goals; Gynecologic Oncology Group; Health; Intensity-Modulated Radiotherapy; Knowledge; Lymphocyte; Malignant Neoplasms; Matched-Pair Analysis; Methodology; Modeling; Native Americans; North Central Cancer Treatment Group; Outcome; Palliative Care; Patients; Pattern; Population; Quality of life; Radiation; Radiation Therapy Oncology Group; Radiation therapy; Research Personnel; Rest; Screening for cancer; Services; South Dakota; Staging; Survival Rate; Target Populations; Toxic effect; Translational Research; Walking; Wisconsin; base; cancer care; cancer diagnosis; cancer initiation; cancer therapy; design; improved; in vivo; irradiation; medically underserved; member; migration; mortality; northern plains; oncology; prevent; programs; response; rural area; satisfaction

DESCRIPTION (provided by applicant): The primary goal of this initiative is to address and hopefully reduce the high, and ominously increasing, cancer mortality rates among American Indians (Als) in western South Dakota, which is 30% higher as compared to that of the overall US population. The specific aims of this project are: (1) to utilize a comprehensive model of patient navigation (PN) services to improve the following cancer-related health outcomes in our target population: to increase cancer screening rates; to decrease delays between abnormal finding, cancer diagnosis and initiation of cancer treatment, to decrease the average stage at which cancer presents, to increase cancer survival rates, and to increase access to palliative care and other services to manage the complex disease states of our clients. Evaluation of these efforts will employ a "utilization-focused" methodology to document progress and guide future efforts. (2) to further expand the scope of clinical cancer trials and to enroll more AI patients, as well as all medically underserved patients in our rural area, to NCI sponsored clinical trials for the more common cancer disease sites. In addition to participation in Cooperative Group trials (e.g. NCCTG, RTOG, GOG), Investigator initiated trials such as IMRT and brachytherapy studies will be opened. Participation in the Wisconsin Oncology Network (WON) will also be initiated to broaden the availability of studies for the more common tumors that are seen in this area. (3) to expand the scope of current translational research to include radiogenomics that will allow investigating genetic risk profiles specifically related to radiation induced toxicity among AI patients by identifying genes through DNA microarrays that might predict response to treatment and ultimately guide therapy. This would include comparing lymphocytic genetic responses to irradiation from patients who had adverse reactions following irradiation to those who have not. A genetic signature could then be developed that would identify susceptible patients prior to radiation therapy.

描述（由申请人提供）：